OKYO Pharma Limited (OKYO) Gamma Exposure (GEX) & Greeks

Gamma exposure (GEX) analysis shows how options positioning creates dealer hedging pressure across strikes. Includes delta, vanna, charm, vomma, and vega exposure by strike price.

OKYO Pharma Limited (OKYO) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $57.2M, listed on NASDAQ, employing roughly 4 people, carrying a beta of 0.04 to the broader market. OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Led by Robert J. Dempsey, public since 2022-05-17.

Greeks exposure analysis shows dealer hedging pressure across strike prices for all six Greeks. No recent options activity for OKYO as of 2026-07-17; this typically reflects low options liquidity, a recently listed name, or a temporary data feed delay. Snapshot will refresh on the next active session.

Learn how gamma exposure is reported and how to read the data →